Cell Culture

News Flash:

Goodwin Biotechnology Teams with Panacea Pharmaceuticals in Overcoming a Significant Bioconjugation Challenge for an Anti‐Cancer Monoclonal Antibody
Aspyrian's Photoimmunotherapy Based on the IRDye 700Dx Platform Shows Efficacy in a Number of Studies. ADC Review / J of Antibody-Drug Conjugates. October, 2015.
Goodwin Biotechnology, Inc. was Honoured with a 2015 Best in Sector Performance Award
Goodwin Biotechnology Announces the Completion of cGMP Manufacturing of an IgM Monoclonal Antibody and IgM : Ligand Conjugate for Q Therapeutics, and Successful Clearance of Q Therapeutics’ IND Submission for Q‐Cells® Cell Therapy in ALS

Goodwin Biotechnology Presented at the BioProcess International Meeting

Emphaze® AEX as the Utility Infielder of Your Downstream Toolbox

We presented data from a chimeric mAb purification utilizing the AEX device as a post-clarification step promoting increased capacity and decreased fouling of the subsequent protein A column. Also, we will present data from an huIgG1 purification where AEX was employed as a polishing step post-CIEX. In both cases we will examine removal or reduction in residuals, including viral clearance data and resulting product quality attributes.

Jack Vicalvi, Manager, Purification & Bioconjugation, Downstream Process Development, Goodwin Biotechnology, Inc.

For more information on Jack Vicalvi's presentation please click here

Purification

Bioconjugation

Biosimilars

Whether you are developing a mammalian cell culture-derived Monoclonal Antibody, Recombinant Protein, or Vaccine, you should consider Goodwin Biotechnology as your development and cGMP manufacturing partner, more...

With an extensive background in the purification of proteins from mammalian, plant and animal transgenic systems, Goodwin Biotechnology can quickly develop a purification process for subsequent cGMP manufacturing, more...

Goodwin Biotechnology offers a unique and unrivaled expertise in the research, process development, validation and cGMP manufacture of Antibody Drug Conjugates (ADCs), radioimmunoconjugates, and other protein more...

When developing a Biosimilar, companies will need to provide a significant amount of analytical, physical and clinical evidence to demonstrate that it is highly similar to the innovator. At Goodwin more...